Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02933242 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Dec 2025 to Aug 2026 Primary endpoints: details revised at 1 of 6 entries · Completion pushed from Jul 2026 to Jul 2027 · Eligibility criteria expanded, about 41 words · 1 more Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 6 entries
    • Completion pushed from Jul 2026 to Jul 2027
    • Eligibility criteria expanded, about 41 words
    • Publications: details revised at 15 of 15 entries
  2. Primary completion date: Jul 2025 to Dec 2025 Completion date: Jul 2025 to Jul 2026v13 Show 1 more changeShow less
    • Completion date: Jul 2025 to Jul 2026
  3. 3 versions Re-verified since Apr 6, 2022, no change to tracked fieldsv10-v12
  4. Primary completion date: Oct 2022 to Jul 2025 Primary endpoints revised (6) · Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 400 to confirmed 399 · 4 morev9 Show 7 more changesShow less
    • Primary endpoints revised (6)
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 399
    • Completion date: Oct 2023 to Jul 2025
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: 6 to 3
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  5. Study site revisedv8 See this version in full on ClinicalTrials.gov ↗
Show 6 earlier versionsHide 6 earlier versions
  1. Study site revisedv7 See this version in full on ClinicalTrials.gov ↗
  2. Enrollment target: 200 to 400v6
  3. Phase: Phase 2 to Not applicablev5
  4. Eligibility criteria expanded, about 65 wordsv4 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 100 to 200 · Study sites: 0 to 1 · Start date: Oct 2016 to Nov 2016 · 2 morev3 Show 5 more changesShow less
    • Enrollment target: 100 to 200
    • Study sites: 0 to 1
    • Start date: Oct 2016 to Nov 2016
    • Eligibility criteria shortened, about 14 words
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  6. Primary endpoints revised (6)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
Trial Details
NCT Number NCT02933242
Lead Sponsor British Columbia Cancer Agency
Conditions Metastatic Tumors
Enrollment 399 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov